Business briefs: Otsuka, GSK, California health exchanges

Share this article:

Japanese drugmaker Otsuka said today it will buy Astex Pharmaceuticals for $886 million. Astex reported positive Phase II mid-stage results last month for its bone cancer treatment. Currently, Astex has one approved drug, Dacogen, which treats myelodysplastic syndromes—a blood disorder.

A melanoma vaccine from British drugmaker GSK fell short in late-stage trials. The treatment, MAGE-A3, did not extend disease-free survival compared to placebo—failing to meet its primary endpoint.

Health exchange consumers in California will be able to compare prices online, the Los Angeles Times reported. An online tool lets consumers see price information for all plans sold in their area.

Share this article:

Email Newsletters

More in Business Briefs

Novartis apologizes for slow reporting

Novartis is apologizing to Japan after the Ministry of Health, Labor and Welfare said the company had dragged its feet reporting adverse events for two of its cancer drugs.

J&J pulls morcellator from market

The company is calling the move a withdrawal, as opposed to a recall.

Pfizer buys two Baxter vaccines

The meningitis and encephalitis medications earned a combined $300 million last year.